Brad Youngblood - Allakos Head Research
| ALLK Stock | USD 0.89 0.02 2.30% |
Insider
Brad Youngblood is Head Research of Allakos
| Phone | 650 597 5002 |
| Web | https://www.allakos.com |
Allakos Management Efficiency
The company has return on total asset (ROA) of (0.4875) % which means that it has lost $0.4875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2168) %, meaning that it created substantial loss on money invested by shareholders. Allakos' management efficiency ratios could be used to measure how well Allakos manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Matthew JD | Arvinas | 49 | |
| YuWaye MD | Fate Therapeutics | N/A | |
| Dr MBA | Blueprint Medicines Corp | 54 | |
| Utpal MBA | Atara Biotherapeutics | 53 | |
| ChB MB | Sangamo Therapeutics | 59 | |
| FACS FACS | Allogene Therapeutics | 73 | |
| Nicole White | Assembly Biosciences | N/A | |
| Path FRCP | Revolution Medicines | 61 | |
| Aron Feingold | Sangamo Therapeutics | N/A | |
| Whitney Jones | Sangamo Therapeutics | N/A | |
| Edward III | Fate Therapeutics | 48 | |
| John II | Ultragenyx | 58 | |
| Justin Skoble | Caribou Biosciences | N/A | |
| Mirella Toro | Annexon | N/A | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| Nicole Lambert | Arcus Biosciences | 46 | |
| Marc MD | Kura Oncology | 50 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| MD FACP | NextCure | 71 | |
| Walter Reiher | Revolution Medicines | N/A | |
| Lisa Peraza | Heron Therapeuti | 47 | |
Management Performance
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.49 |
Allakos Leadership Team
Elected by the shareholders, the Allakos' board of directors comprises two types of representatives: Allakos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allakos. The board's role is to monitor Allakos' management team and ensure that shareholders' interests are well served. Allakos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allakos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan Chang, Director Analytics | ||
| Brad Youngblood, Head Research | ||
| Craig MD, Chief Officer | ||
| Henrik Rasmussen, Chief Medical Officer | ||
| Adam Tomasi, President | ||
| Baird III, Chief Officer | ||
| Mary Cromwell, Chief Officer | ||
| Robert Alexander, CEO, Director | ||
| MPH MD, Chief Officer |
Allakos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allakos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | 23.91 M | ||||
| Shares Outstanding | 89.34 M | ||||
| Shares Owned By Insiders | 2.31 % | ||||
| Shares Owned By Institutions | 81.63 % | ||||
| Number Of Shares Shorted | 1.71 M | ||||
| Price To Earning | (21.26) X | ||||
| Price To Book | 1.08 X | ||||
| EBITDA | (189.91 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allakos. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Allakos Stock please use our How to buy in Allakos Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allakos. If investors know Allakos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allakos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allakos is measured differently than its book value, which is the value of Allakos that is recorded on the company's balance sheet. Investors also form their own opinion of Allakos' value that differs from its market value or its book value, called intrinsic value, which is Allakos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allakos' market value can be influenced by many factors that don't directly affect Allakos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allakos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allakos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allakos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.